Skip to content

Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals

Intramedullary Nailing of the Femur: A Comparison of the Trochanteric and Piriformis Starting Portals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00593333
Acronym
TROCHNAIL
Enrollment
110
Registered
2008-01-15
Start date
2003-06-30
Completion date
2008-12-31
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femur Fracture

Keywords

Femur Fracture, Intramedullary Nailing, Trochanteric Nailing, Piriformis Starting Portal, Trochanteric Insertion Portal

Brief summary

This project is designed to determine whether or not the trochanteric insertion portal will show any difference when compared with the piriformis fossa portal in terms of pain and strength of the hip abductor muscles, while allowing faster surgical fixation of the femur fracture.

Detailed description

This project is designed as a prospective, randomized, comparative study between the Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis) and a standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur. The hypothesis is that the trochanteric insertion portal will have no difference when compared with the piriformis fossa portal in terms of pain and strength of the hip abductor muscles, while allowing faster surgical fixation of the femur fracture. Any patient who has sustained a fracture of the femur, is at least 19 years of age, and meets the study's inclusion and exclusion criteria will be asked to participate in the study. After informed consent has been obtained, the patient will be taken to the Operating Theater for surgical fixation of the femur fracture. No fracture will be entered into the study unless antegrade femoral nailing is the treatment of choice of the attending surgeon. The outcome variables consist of the intraoperative and postoperative adverse device effects recorded in the medical record and on the study data collection form, intraoperative and postoperative complications recorded in medical record and on the study data collection form, hip functional outcome using the WOMAC score recorded for each patient, SF-36 score recorded for each patient, results of clinical examination at 6 weeks, 3, 6, and 12 months recorded in medical record and on the study data collection form, radiographic examination evaluated by two surgeons for the presence of callus and radiographic healing recorded in the medical record and on the study data collection form. Radiographic healing at 6 weeks, 3, 6, and 12 months recorded in the medical record and on the study data collection form. (The injury severity score for all multiple trauma patients recorded on the study data collection form, and soft tissue score according to Gustillo and Anderson for open injuries and according to Tscherne for all closed injuries recorded on the study data collection form. This data will be taken into account relative to the outcome variables). The effects will be measured by clinical examination, radiographic examination, and subjective patient's outcome survey. Additionally, hip abductor muscle strength will be measured and ability to perform one leg stance and hop will be documented at 6 and 12 months. Data will be collected and entered into EXCEL spreadsheets with double keying for quality control purposes and managed by the Department of Orthopaedic Surgery at the University of Alabama at Birmingham (UAB). After data entry is complete, the file(s) will be copied to diskette and delivered to the UAB Biostatistics statistician for analysis and report generation. The analysis will involve simple descriptive statistics (means, standard deviations, proportions) to assure balance of the treatment groups with respect to relevant variables. T-test will be used to compare the mean times to callus formation and radiographic healing between groups. Analysis of covariance will be performed if there are variables that require adjustment. Growth curve analysis (survival models) and Cox regression procedures will be used to compare the rates of callus formation and/or healing between the two groups. Assumption of proportional hazards in the model will be verified before attempting Cox regression procedures. P-values will be computed using a Mann-Whitney U test for non-parametric data.

Interventions

DEVICEAntegrade Intramedullary Nail

Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.

DEVICETrigen Trochanteric Femoral Nail

Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.

Sponsors

Smith & Nephew, Inc.
CollaboratorINDUSTRY
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fracture patterns of the proximal or middle thirds of the femur that will allow antegrade insertion of a femoral nail * Adult patient (19 years and older)

Exclusion criteria

* Nonunions of the femur * Pathologic fractures * Documented prior femur fractures with surgical stabilization with an antegrade nail * Patients who are pregnant, mentally disturbed, or prisoners * Inability to comply with protocol * Patients or family members who are unable or unwilling to sign study consent * Any fracture too proximal or too distal to use an interlocking screw

Design outcomes

Primary

MeasureTime frameDescription
Healed Femur Fracturebaseline to healed fracture (weeks)Time to clinically healed fracture as measured by weeks.

Countries

United States

Participant flow

Recruitment details

Study started in June 2003. Primary completion date December 2008. Study completion date December 2008. Patients were recruited at University of Alabama at Birmingham.

Participants by arm

ArmCount
Standard Treatment
Pirformis fossa entry portal for the antegrade nailing was used for this group. Received either a TRIGEN antegrade femoral nail or an Antegrade Femoral Nail.
54
Trigen
Trochanteric entry portal for the antegrade nailing was used for this group. These subjects received a TRigen Trochanteric Angegrade Nail (TAN) that incorporates a 4 degree valgus bend in the proximal aspect of the nail.
56
Total110

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up1011

Baseline characteristics

CharacteristicStandard TreatmentTrigenTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants2 Participants3 Participants
Age, Categorical
Between 18 and 65 years
53 Participants54 Participants107 Participants
Sex: Female, Male
Female
11 Participants16 Participants27 Participants
Sex: Female, Male
Male
43 Participants40 Participants83 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 540 / 56
other
Total, other adverse events
7 / 548 / 56
serious
Total, serious adverse events
3 / 541 / 56

Outcome results

Primary

Healed Femur Fracture

Time to clinically healed fracture as measured by weeks.

Time frame: baseline to healed fracture (weeks)

ArmMeasureValue (MEAN)
Standard TreatmentHealed Femur Fracture31.8 Weeks
TrigenHealed Femur Fracture31.4 Weeks

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026